Helicobacter pylori infection is not associated with nonalcoholic fatty liver disease

World Journal of Gastroenterology

Volumn 22, Issue 8, 2016, Pages 2592-2600

  Baeg, Myong Ki ^a   Yoon, Seung Kew ^a   Ko, Sun Hye ^a   Noh, Yong Sun ^a   Lee, In Seok ^a   Choi, Myung Gyu ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

Helicobacter pylori; Hepatic steatosis index; Nonalcoholic fatty liver disease; Nonalcoholic fatty liver disease liver fat score; Urea breath test

Indexed keywords

C REACTIVE PROTEIN; CARBON 13;

ADULT; ARTICLE; BODY MASS; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; HELICOBACTER INFECTION; HEPATIC STEATOSIS INDEX; HEPATOBILIARY PARAMETERS; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MEDICAL HISTORY; NONALCOHOLIC FATTY LIVER; RETROSPECTIVE STUDY; SMOKING; UREA BREATH TEST; CHI SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDY; HEALTH SURVEY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; ODDS RATIO; RISK ASSESSMENT; RISK FACTOR; SOUTH KOREA; STATISTICAL MODEL;

ADULT; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH SURVEYS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; ODDS RATIO; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 84959911085     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i8.2592     Document Type: Article

References (47)

1. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395 [PMID: 15565570 DOI: 10.1002/hep.20466]
2. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015; 313: 2263-2273 [PMID: 26057287 DOI: 10.1001/jama.2015.5370]
3. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-1219 [PMID: 12717402 DOI: 10.1053/jhep.2003.50193]
4. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013; 10: 330-344 [PMID: 23507799 DOI: 10.1038/nrgastro.2013.41]
5. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ, Camporez JP, Shulman GI, Gordon JI, Hoffman HM, Flavell RA. Inflammasomemediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012; 482: 179-185 [PMID: 22297845 DOI: 10.1038/nature10809]
6. Le Roy T, Llopis M, Lepage P, Bruneau A, Rabot S, Bevilacqua C, Martin P, Philippe C, Walker F, Bado A, Perlemuter G, Cassard-Doulcier AM, Gérard P. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 2013; 62: 1787-1794 [PMID: 23197411 DOI: 10.1136/gutjnl-2012-303816]
7. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, Mascianà R, Forgione A, Gabrieli ML, Perotti G, Vecchio FM, Rapaccini G, Gasbarrini G, Day CP, Grieco A. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49: 1877-1887 [PMID: 19291785 DOI: 10.1002/hep.22848]
8. Nieuwdorp M, Gilijamse PW, Pai N, Kaplan LM. Role of the microbiome in energy regulation and metabolism. Gastroenterology 2014; 146: 1525-1533 [PMID: 24560870 DOI: 10.1053/j.gastro.2014.02.008]
9. Ding S, Chi MM, Scull BP, Rigby R, Schwerbrock NM, Magness S, Jobin C, Lund PK. High-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse. PLoS One 2010; 5: e12191 [PMID: 20808947 DOI: 10.1371/journal.pone.0012191]
10. Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, Muccioli GG, Delzenne NM. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009; 58: 1091-1103 [PMID: 19240062 DOI: 10.1136/gut.2008.165886]
11. Claus SP, Tsang TM, Wang Y, Cloarec O, Skordi E, Martin FP, Rezzi S, Ross A, Kochhar S, Holmes E, Nicholson JK. Systemic multicompartmental effects of the gut microbiome on mouse metabolic phenotypes. Mol Syst Biol 2008; 4: 219 [PMID: 18854818 DOI: 10.1038/msb.2008.56]
12. Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, Gill SR. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013; 57: 601-609 [PMID: 23055155 DOI: 10.1002/hep.26093]
13. Malfertheiner P, Venerito M, Selgrad M. Helicobacter pylori infection: selected aspects in clinical management. Curr Opin Gastroenterol 2013; 29: 669-675 [PMID: 24100726 DOI: 10.1097/MOG.0b013e328365d443]
14. Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006; 19: 449-490 [PMID: 16847081 DOI: 10.1128/cmr.00054-05]
15. Buzás GM. Metabolic consequences of Helicobacter pylori infection and eradication. World J Gastroenterol 2014; 20: 5226-5234 [PMID: 24833852 DOI: 10.3748/wjg.v20.i18.5226]
16. Li M, Shen Z, Li YM. Potential role of Helicobacter pylori infection in nonalcoholic fatty liver disease. World J Gastroenterol 2013; 19: 7024-7031 [PMID: 24222944 DOI: 10.3748/wjg.v19. i41.7024]
17. Eshraghian A, Hashemi SA, Hamidian Jahromi A, Eshraghian H, Masoompour SM, Davarpanah MA, Eshraghian K, Taghavi SA. Helicobacter pylori infection as a risk factor for insulin resistance. Dig Dis Sci 2009; 54: 1966-1970 [PMID: 19009348 DOI: 10.1007/s10620-008-0557-7]
18. Eshraghian A, Eshraghian H, Ranjbar Omrani G. Insulin resistance and metabolic syndrome: is Helicobacter pylori criminal? Minerva Gastroenterol Dietol 2011; 57: 379-385 [PMID: 22105726]
19. Jamali R, Mofid A, Vahedi H, Farzaneh R, Dowlatshahi S. The effect of helicobacter pylori eradication on liver fat content in subjects with non-alcoholic Fatty liver disease: a randomized openlabel clinical trial. Hepat Mon 2013; 13: e14679 [PMID: 24358044 DOI: 10.5812/hepatmon.14679]
20. Polyzos SA, Kountouras J, Papatheodorou A, Patsiaoura K, Katsiki E, Zafeiriadou E, Zavos C, Anastasiadou K, Terpos E. Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism 2013; 62: 121-126 [PMID: 22841522 DOI: 10.1016/j.metabol.2012.06.007]
21. Okushin K, Takahashi Y, Yamamichi N, Shimamoto T, Enooku K, Fujinaga H, Tsutsumi T, Shintani Y, Sakaguchi Y, Ono S, Kodashima S, Fujishiro M, Moriya K, Yotsuyanagi H, Mitsushima T, Koike K. Helicobacter pylori infection is not associated with fatty liver disease incluDing non-alcoholic fatty liver disease: a large-scale cross-sectional study in Japan. BMC Gastroenterol 2015; 15: 25 [PMID: 25880912 DOI: 10.1186/s12876-015-0247-9]
22. Sumida Y, Kanemasa K, Imai S, Mori K, Tanaka S, Shimokobe H, Kitamura Y, Fukumoto K, Kakutani A, Ohno T, Taketani H, Seko Y, Ishiba H, Hara T, Okajima A, Yamaguchi K, Moriguchi M, Mitsuyoshi H, Yasui K, Minami M, Itoh Y. Helicobacter pylori infection might have a potential role in hepatocyte ballooning in nonalcoholic fatty liver disease. J Gastroenterol 2015; 50: 996-1004 [PMID: 25622927 DOI: 10.1007/s00535-015-1039-2]
23. Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, Kim YJ, Yoon JH, Cho SH, Sung MW, Lee HS. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 2010; 42: 503-508 [PMID: 19766548 DOI: 10.1016/j.dld.2009.08.002]
24. Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, Lundbom N, Rissanen A, Ridderstråle M, Groop L, Orho-Melander M, Yki-Järvinen H. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 2009; 137: 865-872 [PMID: 19524579 DOI: 10.1053/j.gastro.2009.06.005]
25. Oh SW. Obesity and metabolic syndrome in Korea. Diabetes Metab J 2011; 35: 561-566 [PMID: 22247896 DOI: 10.4093/dmj.2011.35.6.561]
26. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645 [PMID: 19805654 DOI: 10.1161/circulationaha.109.192644]
27. Polyzos SA, Kountouras J, Zavos C, Deretzi G. The association between Helicobacter pylori infection and insulin resistance: a systematic review. Helicobacter 2011; 16: 79-88 [PMID: 21435084 DOI: 10.1111/j.1523-5378.2011.00822.x]
28. Gunji T, Matsuhashi N, Sato H, Fujibayashi K, Okumura M, Sasabe N, Urabe A. Helicobacter pylori infection is significantly associated with metabolic syndrome in the Japanese population. Am J Gastroenterol 2008; 103: 3005-3010 [PMID: 19086952 DOI: 10.1111/j.1572-0241.2008.02151.x]
29. Day CP, James OF. Steatohepatitis: a tale of two hits? Gastroenterology 1998; 114: 842-845 [PMID: 9547102]
30. Duseja A, Chawla YK. Obesity and NAFLD: the role of bacteria and microbiota. Clin Liver Dis 2014; 18: 59-71 [PMID: 24274865 DOI: 10.1016/j.cld.2013.09.002]
31. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM 2010; 103: 71-83 [PMID: 19914930 DOI: 10.1093/qjmed/hcp158]
32. Cindoruk M, Cirak MY, Unal S, Karakan T, Erkan G, Engin D, Dumlu S, Turet S. Identification of Helicobacter species by 16S rDNA PCR and sequence analysis in human liver samples from patients with various etiologies of benign liver diseases. Eur J Gastroenterol Hepatol 2008; 20: 33-36 [PMID: 18090988 DOI: 10.1097/MEG.0b013e3282efa4f2]
33. Doan Z, Filik L, Ergül B, Sarikaya M, Akbal E. Association between Helicobacter pylori and liver-to-spleen ratio: a randomized-controlled single-blind study. Eur J Gastroenterol Hepatol 2013; 25: 107-110 [PMID: 23013624 DOI: 10.1097/MEG.0b013e3283590c10]
34. Takuma Y. [Helicobacter pylori infection and liver diseases]. Gan To Kagaku Ryoho 2011; 38: 362-364 [PMID: 21403438]
35. Gen R, Demir M, Ataseven H. Effect of Helicobacter pylori eradication on insulin resistance, serum lipids and low-grade inflammation. South Med J 2010; 103: 190-196 [PMID: 20134372 DOI: 10.1097/SMJ.0b013e3181cf373f]
36. Polyzos SA, Nikolopoulos P, Stogianni A, Romiopoulos I, Katsinelos P, Kountouras J. Effect of Helicobacter pylori eradication on hepatic steatosis, NAFLD fibrosis score and HSENSI in patients with nonalcoholic steatohepatitis: a MR imaging-based pilot open-label study. Arq Gastroenterol 2014; 51: 261-268 [PMID: 25296089]
37. Khosravi Y, Seow SW, Amoyo AA, Chiow KH, Tan TL, Wong WY, Poh QH, Sentosa IM, Bunte RM, Pettersson S, Loke MF, Vadivelu J. Helicobacter pylori infection can affect energy modulating hormones and body weight in germ free mice. Sci Rep 2015; 5: 8731 [PMID: 25736205 DOI: 10.1038/srep08731]
38. Burucoa C, Delchier JC, Courillon-Mallet A, de Korwin JD, Mégraud F, Zerbib F, Raymond J, Fauchère JL. Comparative evaluation of 29 commercial Helicobacter pylori serological kits. Helicobacter 2013; 18: 169-179 [PMID: 23316886 DOI: 10.1111/hel.12030]
39. Meffert PJ, Baumeister SE, Lerch MM, Mayerle J, Kratzer W, Völzke H. Development, external validation, and comparative assessment of a new diagnostic score for hepatic steatosis. Am J Gastroenterol 2014; 109: 1404-1414 [PMID: 24957156 DOI: 10.1038/ajg.2014.155]
40. Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratziu V. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2014; 40: 1209-1222 [PMID: 25267215 DOI: 10.1111/apt.12963]
41. Kahl S, Straßburger K, Nowotny B, Livingstone R, Klüppelholz B, Keßel K, Hwang JH, Giani G, Hoffmann B, Pacini G, Gastaldelli A, Roden M. Comparison of liver fat indices for the diagnosis of hepatic steatosis and insulin resistance. PLoS One 2014; 9: e94059 [PMID: 24732091 DOI: 10.1371/journal.pone.0094059]
42. Kim BH, Kim YJ, Jeong SH, Tak WY, Ahn SH, Lee YJ, Jung EU, Lee JI, Yeon JE, Hwang JS, Um SH, Seo YS, Kim YS, Song BC, Kim JH, Jung YK, Park CK, Kim KA, Min HJ, Cho EY, Lee ES, Kwon SY, Chae HB, Kim DJ, Shin SR. Clinical features of autoimmune hepatitis and comparison of two diagnostic criteria in Korea: a nationwide, multicenter study. J Gastroenterol Hepatol 2013; 28: 128-134 [PMID: 23033899 DOI: 10.1111/j.1440-1746.2012.07292.x]
43. Kim GH, Yang JY, Park JY, Lee JJ, Kim JH, Yoo HW. Estimation of Wilson's disease incidence and carrier frequency in the Korean population by screening ATP7B major mutations in newborn filter papers using the SYBR green intercalator method based on the amplification refractory mutation system. Genet Test 2008; 12: 395-399 [PMID: 18652531 DOI: 10.1089/gte.2008.0016]
44. Ko DH, Chang HE, Song SH, Yoon H, Park KU, Song J. Identification of compound heterozygous mutation in a Korean patient with alpha 1-antitrypsin deficiency. Korean J Lab Med 2011; 31: 294-297 [PMID: 22016686 DOI: 10.3343/kjlm.2011.31.4.294]
45. Jung H, Ki CS, Koh WJ, Ahn KM, Lee SI, Kim JH, Ko JS, Seo JK, Cha SI, Lee ES, Kim JW. Heterogeneous spectrum of CFTR gene mutations in Korean patients with cystic fibrosis. Korean J Lab Med 2011; 31: 219-224 [PMID: 21779199 DOI: 10.3343/kjlm.2011.31.3.219]
46. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997; 34: 275-278 [PMID: 9138148]
47. Gweon TG, Lim CH, Byeon SW, Baeg MK, Lee JY, Moon SJ, Kim JS, Choi MG. [A case of celiac disease]. Korean J Gastroenterol 2013; 61: 338-342 [PMID: 23877215]